Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V501 (Gardasil) Phase II Efficacy Study in Women
NCT00378560Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Primary completion
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
01
Overview
A Phase 2 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Merck & Co.. Started Jun 2006; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT00378560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378560.